{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010774","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.585716+00:00","generated_at":"2026-05-17T17:44:17.544261+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure acquires global rights to CDH6 ADC SIM0505; Q2 net loss $26.8M","bullets":["Strategic partnership with Simcere Zaiming for SIM0505 (CDH6 ADC); NextCure holds rights ex-China.","First US patient dosing for SIM0505 expected in Q3 2025; Phase 1 data in China showed partial response.","LNCB74 (B7-H4 ADC) Phase 1 in cohort 4; backfill cohorts planned H2 2025.","Cash $35.3M as of June 30, 2025; expects to fund operations into mid-2026.","Simcere Zaiming made $2M equity investment; regained Nasdaq minimum bid price compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010774","json":"https://secwatch.observer/filing/0001558370-25-010774.json","markdown":"https://secwatch.observer/filing/0001558370-25-010774.md","text":"https://secwatch.observer/filing/0001558370-25-010774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/0001558370-25-010774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837025010774/nxtc-20250807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:44:17.544261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}